Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
K+ efflux-independent NLRP3 inflammasome activation by small molecules targeting mitochondria.
Immunity 45, 761-773 (2016)
Verlagsversion
Forschungsdaten
DOI
PMC
Imiquimod is a small-molecule ligand of Toll-like receptor-7 (TLR7) that is licensed for the treatment of viral infections and cancers of the skin. Imiquimod has TLR7-independent activities that are mechanistically unexplained, including NLRP3 inflammasome activation in myeloid cells and apoptosis induction in cancer cells. We investigated the mechanism of inflammasome activation by imiquimod and the related molecule CL097 and determined that K+ efflux was dispensable for NLRP3 activation by these compounds. Imiquimod and CL097 inhibited the quinone oxidoreductases NQO2 and mitochondrial Complex I. This induced a burst of reactive oxygen species (ROS) and thiol oxidation, and led to NLRP3 activation via NEK7, a recently identified component of this inflammasome. Metabolic consequences of Complex I inhibition and endolysosomal effects of imiquimod might also contribute to NLRP3 activation. Our results reveal a K+ efflux-independent mechanism for NLRP3 activation and identify targets of imiquimod that might be clinically relevant.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Nalp3 Inflammasome; Immune Cells; Apoptosis; Inhibitor; Disease; Oxygen; Macrophages; Metabolism; Crystals; Death
ISSN (print) / ISBN
1074-7613
e-ISSN
1097-4180
Zeitschrift
Immunity
Quellenangaben
Band: 45,
Heft: 4,
Seiten: 761-773
Verlag
Cell Press
Verlagsort
Cambridge, Mass.
Nichtpatentliteratur
Publikationen
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Diabetes and Obesity (IDO)
Institute of Environmental Medicine (IEM)
Institute of Environmental Medicine (IEM)